Article info

Download PDFPDF
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Authors

  1. Correspondence to Dr Wolfgang Hueber, Novartis Institutes for BioMedical Research, Basel, Switzerland; wolfgang.hueber{at}novartis.com
View Full Text

Citation

Hueber W, Sands BE, Lewitzky S, et al
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Publication history

  • Revised March 14, 2012
  • Accepted March 15, 2012
  • First published May 17, 2012.
Online issue publication 
November 09, 2012

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.